An Observational Study of CellCept (Mycophenolate Mofetil) in Renal Allograft Recipients

Observational, Non-interventional Survey of Renal Allograft Recipients Receiving CellCept as Part of Their Immunosuppressive Protocol

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01707550

Enrollment

414

Registered

2012-10-16

Start date

2009-12-31

Completion date

2011-01-31

Last updated

2016-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Transplantation

Brief summary

This observational survey study will capture all renal transplant patients in Serbia who are currently receiving CellCept (mycophenolate mofetil) as part of their immunosuppressive protocol.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult patients, \>/= 18 years of age * Recipients of renal allograft * Patients receiving CellCept

Exclusion criteria

* N/A

Design outcomes

Primary

Measure	Time frame
Average dose of CellCept used in immunosuppressive protocols in Serbia	9 months
Average dose of concomitant immunosuppressive drugs	9 months

Secondary

Measure	Time frame
Average duration of post-transplant period for patients in Serbia receiving CellCept	9 months

Countries

Serbia

Outcome results